Reversine: Potent Aurora Kinase Inhibitor for Cancer Cell Cycle Research

Executive Summary: Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) is a small molecule inhibitor of Aurora kinases A, B, and C (IC50 values: 150 nM, 500 nM, 400 nM, respectively) that disrupts mitotic regulation and cell cycle checkpoints in cancer cells (APExBIO). It induces dedifferentiation in murine myoblasts and exerts anti-tumor effects by suppressing Aurora kinase expression and inhibiting proliferation in cervical cancer cell lines (Jan et al., 2025). Reversine shows synergistic tumor suppression when combined with aspirin in murine models. The compound is insoluble in water, but soluble in DMSO and ethanol under specified conditions. It is intended strictly for research use, not for diagnostic or therapeutic applications (APExBIO).

Biological Rationale

Aurora kinases (A, B, C) are serine/threonine kinases responsible for crucial mitotic events: centrosome maturation, spindle assembly, and chromosome segregation (Jan et al., 2025). Dysregulation of Aurora kinase signaling contributes to chromosomal instability and tumorigenesis. Inhibitors targeting these kinases can disrupt cell division, impeding cancer cell proliferation (internal article). Reversine was developed as a research tool to selectively inhibit these kinases, enabling precise interrogation of mitotic processes and cancer cell vulnerabilities.

Mechanism of Action of Reversine

Reversine binds to the ATP-binding pocket of Aurora kinases, inhibiting their kinase activity with nanomolar potency (A: 150 nM, B: 500 nM, C: 400 nM; DMSO assays, 25°C). Inhibition of Aurora A disrupts centrosome maturation and spindle assembly, while Aurora B and C inhibition impairs chromosome alignment and cytokinesis (APExBIO). This leads to mitotic checkpoint abrogation, cell cycle arrest, and apoptosis induction in susceptible cancer cells. In murine myoblasts, reversine additionally induces dedifferentiation, indicating broader effects on cell fate determination (Jan et al., 2025).

Evidence & Benchmarks

• Reversine has IC50 values of 150 nM (Aurora A), 500 nM (Aurora B), and 400 nM (Aurora C) against purified enzymes at 25°C in kinase buffer (APExBIO product data; product page).
• Reversine inhibits proliferation of multiple cervical cancer cell lines (HeLa, U14, Siha, Caski, C33A) in vitro with dose-dependent effects (Jan et al., 2025, DOI:10.1063/5.0269550).
• Combination treatment with reversine and aspirin in murine cervical cancer models significantly reduces tumor weight and volume via synergistic growth inhibition and apoptosis induction (Jan et al., 2025, DOI:10.1063/5.0269550).
• Reversine induces dedifferentiation of murine myoblasts, demonstrating effects beyond mitotic inhibition (Jan et al., 2025, DOI:10.1063/5.0269550).
• Reversine is insoluble in water but soluble in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL with warming and ultrasonic treatment), enabling preparation for cellular assays (APExBIO product data; product page).

For a deeper mechanistic dissection of mitotic checkpoint regulation by reversine, see this analysis, which extends the present article by revealing additional checkpoint disruption mechanisms.

For translational perspectives and future strategies, this overview offers insights on how reversine bridges foundational science and actionable lab practice, complementing the evidence benchmarks here.

Applications, Limits & Misconceptions

Reversine (A3760) is widely used in cancer research to investigate Aurora kinase signaling, cell cycle checkpoints, and apoptosis induction. It is valuable for studies on chromosomal segregation, mitotic regulation, and dedifferentiation phenomena in vitro and in vivo. Reversine is not approved for diagnostic or medical use in humans.

Common Pitfalls or Misconceptions

• Not a clinical drug: Reversine is strictly for scientific research and is not licensed for therapeutic or diagnostic use (APExBIO).
• Solubility constraints: Reversine is insoluble in water; improper solvent use (e.g., adding to aqueous buffer directly) will result in precipitation and loss of activity.
• Solution stability: Solutions are not recommended for long-term storage; prompt use after preparation ensures activity (APExBIO).
• Off-target effects: While selective, reversine may affect non-Aurora kinases at high concentrations; proper controls are required to confirm on-target actions.
• Species specificity: Activity profiles may vary between human and murine cells; extrapolation between species should be experimentally validated.

Workflow Integration & Parameters

Reversine is supplied as a solid by APExBIO. Store at -20°C. Prepare stock solutions in DMSO (≥19.65 mg/mL) or ethanol (≥6.69 mg/mL with gentle warming and sonication). For in vitro cell assays, dilute into culture medium immediately before use, ensuring final DMSO/ethanol concentrations are compatible with cell viability (typically ≤0.1%). Solutions should not be stored long-term; prepare fresh for each experiment. For in vivo murine studies, follow validated protocols with appropriate dosages and combination regimens (see Jan et al., 2025 for aspirin co-treatment details). For further detail on workflow integration and checkpoint analysis, see this resource, which clarifies advanced mechanistic applications beyond standard protocols discussed here.

Conclusion & Outlook

Reversine (A3760, APExBIO) is a validated, potent Aurora kinase inhibitor suitable for dissecting mitotic regulation, cell cycle checkpoints, and apoptosis in cancer research. Its precisely characterized selectivity, solubility profile, and evidence base make it an indispensable reagent for researchers exploring the Aurora kinase signaling axis. Ongoing research continues to reveal its utility for understanding dedifferentiation and synergistic anti-tumor strategies. For detailed specifications and ordering, refer to the Reversine product page.